Clinical Trials Logo

Pharmacokinetics of MDV3100 clinical trials

View clinical trials related to Pharmacokinetics of MDV3100.

Filter by:
  • None
  • Page 1

NCT ID: NCT01911728 Completed - Clinical trials for Castration Resistant Prostate Cancer (CRPC)

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Start date: July 25, 2011
Phase: Phase 1
Study type: Interventional

A drug-drug interaction study to investigate the potential pharmacokinetic interaction between MDV3100 and a cocktail of substrates for pioglitazone (CYP2C8 substrate), S-warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A4 substrate).

NCT ID: NCT01911715 Completed - Healthy Subjects Clinical Trials

A Study to Explore the Routes of Elimination of MDV3100

Start date: April 2011
Phase: Phase 1
Study type: Interventional

A study to investigate the excretion routes of radio-labelled MDV3100.

NCT ID: NCT01901133 Completed - Healthy Subjects Clinical Trials

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

Start date: October 2011
Phase: Phase 1
Study type: Interventional

This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects. The study will consist of two treatment arms. Arm A will assess the influence of mild hepatic impairment, and Arm B will assess the influence of moderate hepatic impairment. Data obtained from subjects with hepatic impairment will be compared to data from Body Mass Index (BMI) and age-matched subjects with normal hepatic function.